Advertisement
U.S. markets open in 9 hours 22 minutes

Instil Bio, Inc. (TIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.10-0.31 (-2.50%)
At close: 04:00PM EDT
12.10 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close12.41
Open12.30
Bid11.55 x 1400
Ask11.70 x 900
Day's Range12.10 - 12.52
52 Week Range6.08 - 14.00
Volume14,090
Avg. Volume36,116
Market Cap78.698M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-30.20
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

      Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

    • GlobeNewswire

      Instil Bio Announces Strategic Update

      DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update. Instil has entered into an agreement with a collaborator that has a successful track record of manufacturing and dosing patients with cell therapies to conduct preclinical manufacturing feasibility studies

    • GlobeNewswire

      Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

      DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company’s common stock will begin trading on a reverse stock spli